公开(公告)号：US10053694B2

公开(公告)日：2018-08-21

申请号：US15171883

申请日：2016-06-02

Applicant: The General Hospital Corporation

Inventor： Jeannie T. Lee ,  Jing Zhao ,  Kavitha Sarma ,  Mark Borowsky ,  Toshiro Kendrick Ohsumi

IPC: C12N15/11 ,  C12N15/113 ,  C12Q1/6881 ,  C12Q1/6886 ,  A61K9/127 ,  A61K31/713 ,  C12Q1/6876

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.

公开(公告)号：US09926546B2

公开(公告)日：2018-03-27

申请号：US15249756

申请日：2016-08-29

Applicant: The General Hospital Corporation

Inventor： J. Keith Joung ,  Benjamin Kleinstiver ,  Vikram Pattanayak

IPC: C12N9/16 ,  C12N9/22 ,  C12N15/90

CPC classification number: C12N9/22 ,  C07K2319/00 ,  C07K2319/71 ,  C12N9/16 ,  C12N15/90 ,  C12N15/902 ,  C12N15/907 ,  C12N2800/22 ,  C12Y114/11 ,  C12Y201/01043 ,  C12Y203/01048 ,  C12Y301/00 ,  C12Y305/01098

Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

公开(公告)号：US09816094B2

公开(公告)日：2017-11-14

申请号：US15171706

申请日：2016-06-02

Applicant: The General Hospital Corporation

Inventor： Jeannie T. Lee ,  Jing Zhao ,  Kavitha Sarma ,  Mark Borowsky ,  Toshiro Kendrick Ohsumi

IPC: C12N15/11 ,  C12N15/113 ,  C12Q1/68 ,  A61K9/127 ,  A61K31/713

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.

公开(公告)号：US20170168067A1

公开(公告)日：2017-06-15

申请号：US15118061

申请日：2015-02-11

Applicant: The University of North Carolina at Chapel Hill

Inventor： Xian Chen

IPC: G01N33/68 ,  G01N33/574 ,  G01N33/573

CPC classification number: G01N33/6875 ,  C12Y201/01043 ,  G01N33/573 ,  G01N33/57488 ,  G01N2333/91017 ,  G01N2440/12 ,  G01N2570/00 ,  G01N2800/70 ,  G01N2800/7095

Abstract: Methods for identifying and developing biomarkers based on the characterization of disease-related components of gene-specific chromatin regulatory protein complexes. Chemoprobes that are substrate-competitive and selectively bind enzymatically active enzymes associated with gene-specific chromatin regulatory protein complex can be used to select chromatin complexes associated with a phenotype of interest.

公开(公告)号：US09618513B2

公开(公告)日：2017-04-11

申请号：US14605519

申请日：2015-01-26

Applicant: The Regents of the University of Michigan

Inventor： Weiping Zou ,  Ilona Kryczek

IPC: G01N33/574 ,  C07K16/24 ,  A61K31/7076 ,  A61K45/06 ,  C12N15/113 ,  C12Q1/68 ,  A61K31/7105 ,  A61K31/713

CPC classification number: G01N33/57419 ,  A61K31/7076 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C07K16/244 ,  C07K2317/76 ,  C12N15/1136 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N2333/4706 ,  G01N2333/54 ,  G01N2333/91017 ,  A61K2300/00

Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and/or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.

公开(公告)号：US20140134637A1

公开(公告)日：2014-05-15

申请号：US13092770

申请日：2011-04-22

Applicant: Yusuke Nakamura ,  Yoichi Furukawa ,  Ryuji Hamamoto ,  Shuichi Nakatsuru

Inventor： Yusuke Nakamura ,  Yoichi Furukawa ,  Ryuji Hamamoto ,  Shuichi Nakatsuru

IPC: G01N33/50

CPC classification number: G01N33/5011 ,  C12Q1/48 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N2333/4736 ,  G01N2333/91011 ,  G01N2500/02

Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.

Abstract translation: 本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。 本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。

公开(公告)号：US07563589B2

公开(公告)日：2009-07-21

申请号：US11140659

申请日：2005-05-27

Applicant: Yi Zhang ,  Ru Cao

Inventor： Yi Zhang ,  Ru Cao

IPC: C12Q1/48 ,  C12N9/10

CPC classification number: C12N9/1007 ,  C07K14/82 ,  C07K2319/20 ,  C12N2799/026 ,  C12Y201/01043 ,  G01N2333/91011

Abstract: The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.

Abstract translation: 本发明提供了包含EED，EZH2和SUZ12的复原复合物，其中重构的复合物对组蛋白H3（H3-K27）的赖氨酸27具有组蛋白甲基转移酶（HMTase）活性。 重构的复合物还可以包括RbAp48，AEBP2或两者。 还公开了生产重建复合物的方法，鉴定抑制重构复合物的HTMase活性的化合物的方法和鉴定用于治疗癌症的候选化合物的方法。 还提供了试剂和试剂盒，包括重构的复合物。

公开(公告)号：WO2014151369A3

公开(公告)日：2014-11-20

申请号：PCT/US2014025587

申请日：2014-03-13

Applicant: DANA FARBER CANCER INST INC

Inventor： WALENSKY LOREN D

IPC: C07K14/47 ,  A61K38/17

CPC classification number: C12N9/96 ,  A61K38/00 ,  C07K14/47 ,  C12N9/1007 ,  C12Y201/01043

Abstract: Provided herein are polypeptides containing stabilized therapeutic peptides related to enhancer of zeste homolog 2 (EZH2), histone lysine N-methyltransferase. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.

Abstract translation: 本文提供含有与味精同系物2（EZH2），组蛋白赖氨酸N-甲基转移酶增强子相关的稳定治疗肽的多肽。 还提供了含有这些多肽的组合物和在治疗癌症中使用这些肽的方法，其包括向受试者施用一种多肽。

公开(公告)号：WO2010091049A2

公开(公告)日：2010-08-12

申请号：PCT/US2010/022994

申请日：2010-02-03

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION ,  ZON, Leonard, I. ,  CEOL, Craig ,  HOUVRAS, Yariv, J.

Inventor： ZON, Leonard, I. ,  CEOL, Craig ,  HOUVRAS, Yariv, J.

IPC: C12Q1/68 ,  C12N15/12 ,  G01N33/68 ,  G01N33/574 ,  C07K16/18

CPC classification number: G01N33/5743 ,  A61K39/39558 ,  C07K16/40 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N33/574 ,  G01N2333/91011 ,  G01N2333/91017

Abstract: Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.

Abstract translation: 本文提供了通过确定生物样品中SETDB1的表达水平来诊断癌症的方法。 本文还提供了通过向有需要的受试者施用SETDB1抑制剂来治疗癌症的方法。

公开(公告)号：WO2007004526A3

公开(公告)日：2007-05-10

申请号：PCT/JP2006313038

申请日：2006-06-23

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  FURUKAWA YOICHI ,  HAMAMOTO RYUJI ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  FURUKAWA YOICHI ,  HAMAMOTO RYUJI ,  NAKATSURU SHUICHI

IPC: C12Q1/48 ,  A61K38/00 ,  A61P35/00 ,  G01N33/68

CPC classification number: G01N33/5011 ,  C12Q1/48 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N2333/4736 ,  G01N2333/91011 ,  G01N2500/02

Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.

Abstract translation: 本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。 本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。 SMYD3（别名ZNFN3A1）的N-末端截短形式具有较高的甲基化活性。 Lys 824是SMYD3的RB1蛋白上优选的甲基化位点。